Final revised Manuscript

Enhanced visualization of optimal cerebral perfusion pressure over time to support clinical decision making Marcel JH Aries, MD, PhD<sup>13</sup> Robin Wesselink, MBChB<sup>15</sup> Jan Willem J Elting, MD, PHD<sup>2</sup> Joseph Donnelly, MBChB<sup>3</sup> Marek Czosnyka, PhD<sup>3</sup> Ari Ercole, MB BChir, PhD<sup>4</sup> Natasha M Maurits, PhD<sup>2 6\*</sup> & Peter Smielewski, PhD<sup>3\*</sup> <sup>1</sup> Department of Intensive Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands <sup>2</sup> Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands <sup>3</sup> Brain Physics Group, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK <sup>4</sup> Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK <sup>5</sup> Department of Technical Medicine, University of Twente, Enschede, The Netherlands <sup>6</sup> Research School of Behavioural and Cognitive Neurosciences, University of Groningen, Groningen, the Netherlands Correspondence: MJH Aries, Department of Critical Care, University of Groningen, University Medical Centre, Hanzeplein 1, 9700 RB Groningen, The Netherlands; Email: m.j.h.aries@umcg.nl Key words: cerebral autoregulation, cerebral perfusion pressure management; traumatic brain injury Tables:..........; Figures:......2.......; Word count:....1902.......; Abstract count:.....298.... Number of references:.....8..... \*Both authors contributed equally to the manuscript. 

 $\begin{array}{c} 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ \end{array}$ 

 $\begin{array}{r} 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ 60\\ 61\\ 62\\ \end{array}$ 

## 1 Conflicts of interest and sources of funding

2 3 4	Marcel Aries received an unrestricted grant from the Dutch Society of Intensive
5	Care.
6	Joseph Donnelly is supported by a Woolf Fisher Trust Scholarship.
7	The software for brain monitoring ICM+ <sup>®</sup> (www.neurosurg.cam.ac.uk/imcplus)
8	is licensed by the University of Cambridge (Cambridge Enterprise). Peter
9	Smielewski and Marek Czosnyka have a financial interest in a part of the
10	licensing fee.
11 12 13	For the remaining authors none were declared.
14 15 16 17 18 19 20 21 22 23 24 25 26 27	<b>Copyright form disclosures:</b> Dr. Aries disclosed other support (The software for brain monitoring ICM+® [www.neurosurg.cam.ac.uk/icmplus] is licensed by the University of Cambridge [Cambridge Enterprise]. Peter Smielewski and Marek Czosnyka have a financial interest in a part of the licensing fee). Dr. Donnelly received funding from Woolf Fisher Trust, New Zealand (study scholarship). Dr. Czosnyka disclosed other support (Integra Life sciences Speakers Bureau - payment 1500Euro) and received funding from Cambridge Enterprise Ltd, UK. Dr. Maurits received funding from Radboud University Nijmegen. Her institution received funding from EU and from the Princess Beatrix Foundation, the Netherlands. Dr. Smielewski disclosed other support (I have a financial interest in the part of the licensing fees of the software, ICM+, used in data collection and partial analysis for this project). The remaining authors have disclosed that they do not have any potential conflicts of interest.

1	Abstract
2	

**Objective**: Cerebrovascular reactivity can provide a continuously updated

- 4 individualised target for management of CPP, termed CPPopt.
- **Data Sources**: Here we present a concept method of visualisation of
- 6 autoregulation based CPPopt using data of 4 severe TBI patients with ICP

7 monitoring.

- **Conclusions**: The visualization method addresses some of the main drawbacks
- 9 of the original methodology and might bring the potential for its clinical
- 10 application closer.

1 Introduction

Current guidelines for management of severe traumatic brain injury (TBI) patients recommend keeping ICP below 20 mmHg and CPP within the range of 50-70 mmHg.<sup>1</sup> Although some success has been achieved, it ignores substantial injury-specific and patient-specific variability.<sup>2</sup> A recent trial showed lack of any important outcome benefits of applying one particular fixed ICP treatment cut-off value.<sup>3</sup> One promising approach supports the idea of individualizing perfusion treatment strategies guided by the state of cerebral autoregulation.<sup>4-6</sup> Cerebrovascular pressure reactivity represents a key element of autoregulation. The pressure reactivity index (PRx) can be determined as the moving correlation coefficient between ABP and ICP.<sup>7</sup> With this approach active cerebrovascular reactions can be assessed by observing the response of cerebral blood volume and subsequently ICP to slow spontaneous changes in ABP.<sup>8</sup> However, minute-by-minute values of PRx vary over time and require averaging to provide meaningful values. Additionally whilst PRx provides a method for assessing autoregulation, it does not, by itself, suggest any particular course of action in patient management.

One useful way of 'averaging' PRx and at the same time providing it with an
immediate clinical meaning, is to divide its values into different bins according to
corresponding predefined CPP ranges. Plotting mean PRx against associated CPP
bins frequently produces a U-shaped curve with both hypoperfusion (low CPP)
and hyperperfusion (high CPP) associated with worsened cerebrovascular
reactivity.<sup>4, 5</sup> Employing curve fitting the lowest point of the individual
autoregulation curve can be marked as the 'optimal' CPP (CPPopt) value,

1	1	corresponding to the CPP where individual autoregulation is the most effective.
2 3	2	These calculations can be repeated every minute from a chosen time range of
4 5 6	3	past data samples (moving window) thus producing a time-trend of CPPopt that
7 8	4	can be plotted alongside of CPP and ICP (Figure 1a). Recently, we have
9 10 11	5	demonstrated that larger deviation of CPP from the automatically calculated
12 13	6	CPPopt was associated with worse clinical outcome. <sup>4</sup> However, the CPPopt trend
14 15 16	7	does not fully reflect the character of the PRx-CPP relationship, nor does it
17 18	8	capture its dynamic nature. In addition, the CPPopt trends can be fairly 'erratic'
19 20 21	9	(noisy), and may often contain many gaps where the PRx-CPP curves cannot
21 22 23	10	robustly be fitted. These effects are likely to be detrimental to the process of
24 25	11	clinical introduction of the autoregulation guided CPP therapy.
26 27 28	12	In this study we therefore aim to improve the CPPopt methodology by
29 30 21	13	introducing a new visualization method that may provide insight into the
32 33	14	complete characteristics of the CPP-PRx relationship, and its temporal evolution.
34 35 36		
37 38	15	Materials and Methods
39 40 41	16	Patients
41 42 43	17	We present the concepts of the new visualization method using data from four
44 45 46	18	randomly selected severe TBI patients who were admitted to the neurocritical
40 47 48	19	care unit in 2013 and underwent monitoring of ICP as part of the TBI
49 50	20	management protocol at the University Medical Center Groningen. The local
51 52 53	21	medical ethics committee waived the need for informed consent. The local TBI
54 55	22	protocol aimed at keeping the CPP at approximately 60-70 mmHg and the ICP
56 57 58	23	below 20 mmHg.
59 60		
6⊥ 62 63		
64 65		

1	Data acquisition
2	ABP was monitored invasively with an intravascular line connected to a pressure
3	transducer (Baxter Healthcare Corp. CardioVascular Group, Irvine, CA) and
4	zeroed at right atrium level. An intraventricular ICP probe (Raumedic Neurovent,
5	Raumedic AG, Helmbrechts, Germany) was used. All monitoring data were stored
6	using ICM+® software (Cambridge Enterprise, Cambridge, UK,
7	http://www.neurosurg.cam.ac.uk/icmplus). Time-averaged means for ABP, ICP
8	CPP (ABP minus ICP), and PRx <sup>7</sup> were calculated and stored every minute.
9	Data processing and visualisation
10	MATLAB (The MathWorks, Inc., Natick, Massachusetts, USA) was used to
11	implement a curve-fitting procedure based on an algorithm described
12	elsewhere <sup>4</sup> in order to retrieve the PRx-CPP curves and the corresponding
13	CPPopt values every minute, with a calculation data buffer of 4 hours .
14	Importantly, all the fitted PRx-CPP curves were extended to cover the whole
15	examined range of CPP, from 40 to 120 mmHg.
16	The sequential PRx-CPP curves were then used to create a colour-coded map of
17	PRx-CPP relationship evolution over time (Figure 1b). The time (horizontal) axis
18	represents the position of the moving window for CPPopt calculation. The fitted
19	values of PRx are color-coded for every CPP-time point in the plot. The cool (blue
20	to yellow) colors represent intact cerebral pressure reactivity while impaired
21	pressure reactivity is represented by hot (orange to red) colors. Black areas
22	represent time points for which no CPPopt could be determined. In the second
23	step a non-causal, exponentially weighted moving average (EWMA) filter ( $n=240$
24	data points (i.e. 240 minutes), $\alpha$ =0.005) was applied to the image along the time
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 20 21 22 23 24

1	1	axis only. This filter has a low-pass (smoothing) effect in time, and moreover it
1 2 3	2	allows to fill in some of the gaps (of duration not exceeding the filter length) with
4 5 6	3	appropriately weighted average of the preceding and following data values
0 7 8	4	(Figure 1c). In a third step the measured CPP (blue line) values were smoothed
9 10 11	5	with the same EWMA filter and added to the image. Finally, the boundaries of the
12 13	6	actual CPP ranges used for individual curve fitting (reflecting the number of
14 15 16	7	included CPP intervals and thereby providing a proxy of the curve reliability) are
17 18	8	indicated with black lines. Transparent overlays on both sides of these black
19 20 21	9	lines make clear within which CPP range the patient was kept and where
21 22 23	10	interpolation of the PRx-CPP curves has taken place. A 'quality' indicator bar was
24 25	11	added on top of the figure, marking sections of the image where the original gaps
26 27 28	12	were present but which were subsequently interpolated by the EWMA filter
29 30	13	(figure 2a).
31 32 33	14	
34 35	15	Results
36 37 38	16	We illustrate the new CPPopt visualization method for the first three monitoring
39 40	17	days of four TBI patients (Figure 2) and provide some retrospective observations
41 42 43	18	that could not have been made with the traditional approach.
44 45	19	In patient 1 (Figure 2a), the PRx-CPP landscape indicates that lower CPP values
46 47 48	20	could have probably been well tolerated on day two. By day three however PRx
49 50	21	becomes positive over the whole CPP range (complete loss of autoregulation). In
51 52 53	22	such situations, autoregulation cannot be optimised and non CPP orientated,
54 55	23	management protocols are probably temporarily more appropriate. In patient 2
56 57 58	24	(Figure 2b) PRx became consistently negative (improving autoregulation) for
59 60	25	CPP values around 70 mmHg on day 2 but in the later part of day 3 the patients'
61 62 63		
64 65		

autoregulation deteriorated considerably suggesting that a more aggressive and targeted management of CPP at higher values (80-90) could have perhaps been attempted. The PRx-CPP image for patient 3, (Figure 2c), tells the opposite story. The patient started off with global loss of autoregulation, then on day 2 the autoregulation seemed to have recovered but only for a relatively narrow and high (75-90) range of CPPs. Subsequently, from day 3 onwards autoregulation recovered over a broad range (55-75) of CPP. Also patient 4 (Figure 2d) started with global loss of autoregulation with the patient kept at very high CPPs (above 90) at end of day 1. Subsequently, from day 3 improved autoregulation in the range 60-75 mmHg might have enabled keeping CPP more 'stable' in this range over time.

**Discussion and conclusions** 

In our previous work<sup>4</sup> we used PRx as a marker of cerebrovascular reactivity to
provide a continuously updated individualised target for management of CPP,
termed CPPopt. Here, we present a visualisation tool which may help clinicians
understand the prevailing physiology in the context of time variation so as to
help them in their decision making in individual patients.

First, by reducing the complexity of the CPP-PRx relationship to a single value
(CPPopt) is an oversimplification that may omit clinically important aspects of
autoregulatory behaviour. For example, in addition to a CPPopt target it is also
useful to understand what the overall autoregulatory capacity is and how
dependent autoregulation is on CPP. Second, the CPPopt time series may
sometimes behave quite erratically with large jumps in CPPopt despite relatively
stable overall clinical condition of the patient. Finally the current CPPopt

1	1	calculation does not always return a valid result at every instant leading to
2 3	2	periods with no data (gaps).
4 5 6	3	Such observations naturally reduce the physiological relevance of any single
7 8	4	value of CPPopt and are probably in part a consequence of the assumptions of
9 10 11	5	the CPPopt calculation including the assessment of autoregulation itself using the
12 13	6	PRx index. Since PRx (and therefore CPPopt) is calculated from spontaneous
14 15 16	7	variations in ICP and ABP rather than diagnostic interventions, it is
17 18	8	fundamentally a statistical parameter, with all uncertainties this brings.
19 20 21	9	The proposed visualisation method attempts to address and ameliorate these
22 23	10	limitations by providing a continuous representation of the relationship between
24 25 26	11	autoregulation and CPP over time. This allows for not only an indicator of the
20 27 28	12	instantaneous CPPopt but also for the full appreciation of the CPP-dependence of
29 30 31	13	autoregulation past and present. The erratic behaviour and 'missing values' of
32 33	14	CPPopt is addressed by smoothly interpolating the CPP-PRx behaviour. This
34 35 36	15	smoothing is physiologically plausible when we consider the timescales of the
37 38	16	underlying pathobiology likely to be responsible for changes in autoregulation
39 40 41	17	are also likely to be in the order of hours-days rather than minutes.
42 43	18	What we describe here is a natural extension of the concept of autoregulatory
44 45 46	19	assessment, providing the full retrospective 'landscape' of PRx-CPP relationship
40 47 48	20	extending over the past several hours. Although further methodological
49 50	21	improvements and a test of functionality are needed, the proposed visualisation,
52 53	22	while addressing some of the problems discussed above, may improve individual
54 55 56	23	CPP management methods based on the status of cerebral autoregulation,
57 58	24	current and past. The visualisation tool could be helpful in the development and
59 60		
₀⊥ 62 63		
64 65		

1	1	fine tuning of an autoregulation-guided CPP treatment protocol that needs
2 3 2	2	prospective testing.
4 5 3	3	
7 4 8	1	
9 10		
11 12		
13 14 15		
16 17		
18 19		
20 21		
22 23 24		
25 26		
27 28		
29 30 31		
32 33		
34 35		
36 37 38		
39 40		
41 42		
43 44 45		
46 47		
48 49 50		
50 51 52		
53 54		
55 56		
57 58 59		
60 61		
62 63		
64 65		

## Acknowledgments

- 3 The software for brain monitoring ICM+<sup>®</sup> (www.neurosurg.cam.ac.uk/icmplus)
- 4 is licensed by the University of Cambridge (Cambridge Enterprise). Peter
- 5 Smielewski and Marek Czosnyka have a financial interest in a part of the
- 6 licensing fee.

## References

1	1	Refe	erences
⊥ 2	2	1	Bratton SL Chastnut DM Chajar L at al Cuidalings for the management of
3	2	1.	Diatton SL, Chestnut KM, Ghajai J, et al. Guidennes foi the management of
4	3		severe traumatic brain injury. IX. Cerebral perfusion thresholds. J
5	4		<i>Neurotrauma</i> 2007;24: S59-S64
6	-	2	
7	5	Ζ.	Maas AI, Menon DK. Traumatic brain injury: rethinking ideas and
8	6		approaches: <i>Lancet Neurol</i> 2012; 11:12-13
10	-	2	
11	7	3.	Chesnut RM, Temkin N, Carney N, et al. A Trial of Intracranial-Pressure
12	8		Monitoring in Traumatic Brain Injury: <i>N Engl J Med</i> 2012; 367:2471-2481
13	0	4	
14	9	4.	Aries MJ, Czosnyka M, Budonoski KP, et al: Continuous determination of
16	10		optimal cerebral perfusion pressure in traumatic brain injury. Crit Care Med
17	11		2012; 40:2456-2463
18	10	_	
19	12	5.	Steiner LA, Czosnyka M, Piechnik SK, et al: Continuous monitoring of
20	13		cerebrovascular pressure reactivity allows determination of optimal
21	14		cerebral perfusion pressure in patients with traumatic brain injury. <i>Crit</i>
22	15		Care Med 2002; 30:733-738
24			
25	16	6.	Le Roux P, Menon DK, Citerio G, et al: Consensus summary statement of the
26	17		International Multidisciplinary Consensus Conference on Multimodality
27	18		Monitoring in Neurocritical Care : A statement for healthcare professionals
28	19		from the Neurocritical Care Society and the European Society of Intensive
29	20		Care Medicine. Intensive Care Med 2014: 40:1189-1209
31			,
32	21	7.	Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD:
33	22		Continuous assessment of the cerebral vasomotor reactivity in head injury.
34	23		<i>Neurosurgery</i> 1997; 41:11-17
36			
37	24	8.	Czosnyka M, Piechnik S, Richards HK, Kirkpatrick P, Smielewski P, Pickard
38	25		JD: Contribution of mathematical modelling to the interpretation of bedside
39	26		tests of cerebrovascular autoregulation. J Neurol Neurosurg Psychiatry
40	27		1997; 63:721-731
41 12	28		,
4.3	29		
44			
45	30		
46	00		
47			
49			
50			
51			
52			
53			
54 55			
56			
57			
58			
59			
60			
б⊥ 62			
63			
64			
65			

**Figure 1** Visualization of the PRx-CPP relationship and 'optimal CPP' (CPPopt) time profile: A) the original visualization showing one curve snapshot and CPPopt time trend (green line)<sup>4</sup>; B) consecutive PRx-CPP curves plotted using a color map, along the time axis; C) as above, but with exponential smoothing added; the final, proposed, complete visualisation image for CPPopt of this patient is in figure 2a. ABP indicates arterial blood pressure; ICP, intracranial pressure; CPP, cerebral perfusion pressure; CPPopt, optimal cerebral perfusion pressure; PRx, pressure reactivity index; PRxopt, optimal pressure reactivity index. Figure 2 Examples of the new visualisation method applied to 4 selected patients, over the first 3 days of monitoring: A) male, 54 years old, fall from roof, GCS of 7, GOS of 4 (moderate disability) B) male, 16 years old, RTA, GCS of 7, GOS of 5 (low disability) C) female, 19 years old, RTA, GCS of 3, GOS of 1 (Death) and D) male, 58 years old, fall of stairs, GCS of 7, GOS of 1 (Death). The blue line indicates the patients' (smoothed) CPP. The Quality Indicator (QI) above the figure shows 'grey' bars indicating interpolated PRx-CPP landscapes (with exponential smoothing) and 'black' bars representing absence of landscape data due to the set smoothing criteria. The 'transparent' areas reflect the CPP intervals where the fitted PRx-CPP curves were extended (interpolated on both sides) to cover the whole examined range of CPP from 40 to 120 mmHg. In that respect the 'black lines' represent the boundaries of the actual CPP ranges used 

24 for individual curve fitting.

Figure legends

- 1 GCS indicates Glasgow Coma score (after resuscitation); RTA, Road Traffic
- 2 Accident; GOS, Glasgow Outcome Scale (at 6 months).
- 2 3 4 5 6 7 8 9 12 13 17 18 21 22 23 27 28 29 31 32 33 37 38 40 42 43 45 46 47 52 57 62



